Scholar Rock Holding Corp — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 82/100
What the filing says
The FDA approved ISEMBYLD (apitegromab-mstn) on September 11, 2026, for spinal muscular atrophy (SMA) in patients aged 2+ currently on SMN2-targeted therapy. The Phase 3 SAPPHIRE trial showed a 2.2-point improvement in Hammersmith Functional Motor Scale-Expanded (HFMSE) vs. placebo (p=0.0121); 34.2% of ISEMBYLD patients achieved a ≥3-point gain vs. 13.5% on placebo (odds ratio 3.8; p=0.0125). Scholar Rock estimates ~6,600 eligible U.S. patients across ~2,600 prescribing physicians and 140 treatment centers; the company holds $492M in cash as of June 30, 2026, and plans to monetize a Rare Pediatric Disease Priority Review Voucher.
Why this rating
First-ever muscle-targeted SMA approval unlocks substantial addressable market (6,600 U.S. patients, ~$2.6B company) with orphan disease pricing power and payer mix; near-term revenue inflection material relative to company size.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $58.50 ▲ 4.62% | at our read · unknown $55.91 | +10 min · unknown $54.97 ▼ 1.70% | +30 min · unknown $54.06 ▼ 3.32% | +1 hr · unknown $53.90 ▼ 3.60% | +4 hrs · unknown $52.81 ▼ 5.55% |
The stock had already moved -4.42% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.